Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Babao Dan Capsule Combined With Antiviral Therapy for HCC Prevention in Hepatitis B-related Cirrhosis
NCT07544121Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in Cirrhosis comparing Standard antiviral therapy + Babao Dan Capsule with Standard antiviral therapy + Placebo (2 arms). Primary endpoint: Hepatocellular carcinoma incidence at 96 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Babaodan
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NCT07544121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544121.